



Press Release

Ondansetron Orally Disintegrating Tablets

Contact:

Suzanne Collier
Marketing Communications
(888) TEVA USA

Teva Introduces Ondansetron Orally Disintegrating Tablets

North Wales, Pennsylvania, July 10, 2007 – Teva Pharmaceuticals is pleased to announce the introduction and availability of Ondansetron Orally Disintegrating Tablets. This product is AB rated and bioequivalent to Zofran ODT[®]* Tablets. Ondansetron Orally Disintegrating Tablets are available in 4 mg in Blister Packs of 30 (5 x 6), and in 8 mg in Blister Packs of 10 (5 x 2) and 30 (5 x 6).

“Generic pharmaceuticals are playing an increasingly important role in healthcare cost containment,” states John Denman, V.P. Sales and Marketing. “Teva Pharmaceuticals continues to lead the way with timely new product launches.”

Teva Pharmaceuticals, located in North Wales, Pennsylvania, is the leading pharmaceutical manufacturer for both new and total prescriptions.[‡] The company has an aggressive Research and Development effort and one of the best overall ANDA approval records in the industry.[‡]

* Zofran ODT[®] is a registered trademark of Glaxo Group Ltd.

‡ Data on file, Teva USA.

Please see accompanying prescribing information.

Administrative Offices:

1090 Horsham Road, P.O. Box 1090, North Wales, PA 19454-1090
Phone: 215.591.3000 Fax: 215.591.8600 www.tevausea.com